MXCT - maxcyte.com Operating income before deduction of amortization

Graphic logo of maxcyte.com (MXCT)

Unique patents deeply integrated into the cycles of pharma behemoths ensure a high barrier to entry. Changes in EBITDA_Co demonstrate profit dynamics, where the indicator settled at 0.00. MaxCyte, Inc. (MXCT) dominates electroporation for CAR-T therapy, leveraging its status as the industry standard. Business growth relies on long-term licenses and the regular sale of consumables for genetic engineering.

MXCT MaxCyte Inc Operating profit before deduction of amortization (11/23/2025 - 11/10/2026)

MaxCyte (MXCT) - metric breakdowns and financial figures

- current price and projected stock value:
Price MaxCyte Inc|MXCT - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization MaxCyte|MXCT - Enterprise Value
- balance sheet equity data:
Accounting Value per Share MaxCyte|MXCT - Company Net Assets|Market Value to Book Value maxcyte.com|MXCT - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio MaxCyte, Inc.|MXCT - Long-Term Debt to Capital|Current Liabilities to Capital MaxCyte Inc.|MXCT - Company Aggregate Debts|Debt to Book Value Ratio MaxCyte|MXCT - Company Long-Term Debts|Short-Term Debt Volume MaxCyte|Quick Liquidity Indicator maxcyte.com
- earnings and multiples data:
MXCT - Net Profit|Projected Future Earnings MaxCyte, Inc.|MXCT - Price to Earnings Ratio|Future Price to Earnings maxcyte.com|MXCT - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation MaxCyte|MXCT - Operating profit EBITDA|Net earnings per one share for the last twelve months MaxCyte|MXCT - Earnings per share for the last twelve months|Net earnings per share growth for the trailing year maxcyte.com|MXCT - Net earnings per share growth this year|Earnings growth forecast for next year MaxCyte, Inc.
Summary company analytics:MaxCyte Inc - MXCT
Mass-produced product of MaxCyte, Inc.

For MaxCyte, Inc., amid geopolitical risks and raw material supply chain vulnerabilities, cash flow analysis via GURU.Markets becomes a critical tool for assessing operational resilience. By examining historical EBITDA_Co data, an investor can identify the net operating result excluding depreciation and taxes, allowing them to differentiate real business efficiency from paper profits during periods of liquidity contraction.

Who MaxCyte, Inc. competes with

Company profit before taxes, interest and amortization ABT (Abbott Corp.)|Thermo Fisher Scientific - Operating profit EBITDA|Operating income before deduction of amortization gehealthcare.com GEHC|MTD: Operating profit EBITDA|Operating profit before deduction of amortization Waters Corp|Operating profit before deduction of amortization TECH|BRKR: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Azenta, Inc. (AZTA)|Operating profit before deduction of amortization vareximaging.com VREX|Operating profit EBITDA SMLR (Semler Scientific)|Butterfly Network Inc (BFLY) - Profit before interest, taxes and amortization|Mesa Labs Corp - Operating profit EBITDA|QSI (Quantum-Si Corporation) - Operating profit before amortization|NNOX: Operating profit EBITDA|QTRX - Operating income before deduction of amortization|MASS (908 Devices) - Operating profit EBITDA|Operating profit before deduction of amortization CapsoVision Medical (CV)|Operating profit EBITDA RPID|Operating profit EBITDA Seer Bio (SEER)|Profit before payment of interest, taxes and amortization Hyperfine, Inc. HYPR|fonar.com - Profit before payment of interest, taxes and amortization|DXR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization MDAI (spectral-ai.com)|VIVS: Operating profit EBITDA|Profit before interest, taxes and amortization Aclarion Corporation (ACON)|Profit before payment of interest, taxes and amortization Akoya Biosciences Inc|THMO - Operating profit before depreciation charges|Operating profit before deduction of amortization TLIS (Talis Biomedical)|Operating profit EBITDA T2 Biosystems Inc. (TTOO)